Homology Medicines, Inc.

NasdaqGS:FIXX 주식 보고서

시가총액: US$54.3m

Homology Medicines 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기no data
CEO 소유권n/a
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간6.2yrs

최근 관리 업데이트

Recent updates

Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

Nov 16
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

Homology Medicines appoints new CEO, chairperson

Sep 06

Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid

Jul 05

Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Jan 28
Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online

Oct 22

We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Sep 18
We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Aug 14
Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

May 22
Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

Homology Medicines (FIXX) Investor Presentation - Slideshow

May 05

Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Apr 17
Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Mar 13
Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

Feb 03
Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

CEO

Homology Medicines 에는 CEO가 없거나 그에 대한 데이터가 없습니다.


이사회 구성원

이름위치테뉴어보상소유권
Saswati Chatterjee
Co-Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Steven S. Gillis
Independent Director8.2yrsUS$69.06k0%
$ 0
Matthew Patterson
Independent Director6.2yrsUS$68.56k0%
$ 0
Beverly Davidson
Chairman of Scientific Advisory Board6.2yrs데이터 없음데이터 없음
Mary Thistle
Independent Director6yrsUS$76.06k0%
$ 0
Mason Freeman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Morton Cowan
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Stephen Elledge
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Arthur Tzianabos
Chairman of the Board7.9yrsUS$1.67m0.22%
$ 120.4k
Jeffrey Poulton
Lead Independent Director3.7yrsUS$68.56k0%
$ 0
Alise Reicin
Independent Director4.7yrsUS$68.22k0%
$ 0
Hans-Peter Kiem
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

6.2yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: FIXX 의 이사회경험(평균 재직 기간 6.2 년)으로 간주됩니다.